Recombinant IgE antibodies for passive immunotherapy of solid tumours: from concept towards clinical application. - Wikidata - awgldk - TriplyDB

Recombinant IgE antibodies for passive immunotherapy of solid tumours: from concept towards clinical application.

Recombinant IgE antibodies for passive immunotherapy of solid tumours: from concept towards clinical application.

http://www.wikidata.org/entity/Q37964490

about

Targeting folate receptor alpha for cancer treatment IgG4 Characteristics and Functions in Cancer Immunity Inverse Association between Prediagnostic IgE Levels and the Risk of Brain Tumors: A Systematic Review and Meta-Analysis IgE immunotherapy against cancer IgE-based Immunotherapy of Cancer -A Comparative Oncology Approach Allergy reduces the risk of meningioma: a meta-analysis Inflammatory adverse events are associated with disease-free survival after vaccine therapy among patients with melanoma.Antibody therapies for melanoma: new and emerging opportunities to activate immunity (Review).Variable Region Identical IgA and IgE to Cryptococcus neoformans Capsular Polysaccharide Manifest Specificity Differences.IgE/FcεRI-Mediated Antigen Cross-Presentation by Dendritic Cells Enhances Anti-Tumor Immune Responses.Establishing the role of tyrosine kinase 2 in cancer.IgE immunotherapy: a novel concept with promise for the treatment of cancer.Comparative reactivity of human IgE to cynomolgus monkey and human effector cells and effects on IgE effector cell potency.Fc-fusion proteins: new developments and future perspectives.Nanotechnology for protein delivery: Overview and perspectives.Structure and dynamics of IgE-receptor interactions: FcεRI and CD23/FcεRII.Pro- and anti-tumour effects of B cells and antibodies in cancer: a comparison of clinical studies and preclinical models.Folate receptor alpha antagonists in preclinical and early stage clinical development for the treatment of epithelial ovarian cancer.The nascent field of AllergoOncology.Insights from Fc receptor biology: a route to improved antibody reagents.Understanding allergy and cancer risk: what are the barriers?Allergy

P2860

Q26744215-21B5E81F-A662-4A63-928A-EF61ABCC498D Q26770244-47B589CE-5489-49A7-AE87-07B520D92A92 Q26785944-121BAE06-8FA6-4E40-9341-F8588C88A112 Q28081223-532C1EDE-ABC1-45F4-9B68-0B35E63B42A8 Q28655505-060EA944-1F73-4667-B02E-87B5A87A6161 Q30365873-BBF15381-EB29-470E-AB82-6157D35D6B45 Q30370026-E308D1A4-2497-4803-BF85-1F17E1BC8400 Q34000700-986C8079-84AA-49AC-B822-6ECFBE92CE64 Q35583106-2A4453FC-C4A8-4EE9-8FFB-8F562DEED861 Q36025549-2CF81F8D-065C-4CD0-9FB9-4AE52AB9C211 Q36643671-737C2CC5-4E71-491E-A9E6-A15185A9985A Q37593712-26877D77-4846-4B0D-8807-B9B7448B94DE Q37698945-F9E51C99-81CB-404E-9719-4FBE98E594DD Q38029985-47630623-AF64-4BE8-B33C-D3A514F82C5D Q38605185-7E95CFF3-FB87-4D07-8D8A-B7C0BBA5A8D2 Q38615378-27C02545-BD16-40F9-8A7E-1337FF0B8A3F Q38843707-7C34854E-7E94-47BE-AAF4-DF432F3A9F71 Q38995020-B53162C2-526F-4D77-B6EA-04C2504BE549 Q40594889-7CD1DDE8-A2AF-4BF4-BF4F-E98AD87C1BE3 Q43177854-25D2B731-DE0A-4C94-8506-09D99CEF1A67 Q57385054-32BFAE1F-5E50-4212-9A6E-36A3A32CBFDF Q58260264-E4256EF3-FE05-4F93-BF15-B2B9319ED9F8

P2860

Recombinant IgE antibodies for passive immunotherapy of solid tumours: from concept towards clinical application.

http://www.wikidata.org/entity/Q37964490

description

article científic

@ca

article scientifique

@fr

articol științific

@ro

articolo scientifico

@it

artigo científico

@gl

artigo científico

@pt

artigo científico

@pt-br

artikel ilmiah

@id

artikull shkencor

@sq

artículo científico

@es

name

Recombinant IgE antibodies for ...... towards clinical application.

@en

Recombinant IgE antibodies for ...... towards clinical application.

@nl

type

label

Recombinant IgE antibodies for ...... towards clinical application.

@en

Recombinant IgE antibodies for ...... towards clinical application.

@nl

prefLabel

Recombinant IgE antibodies for ...... towards clinical application.

@en

Recombinant IgE antibodies for ...... towards clinical application.

@nl

P1433

Q37964490-1DA091EE-0524-4740-A49A-EB655BAF1075

P1476

Q37964490-1E6C2160-F354-4D40-9866-D2F9A8644B67

P2093

Q37964490-146E6559-92BA-4436-B3B5-293918DE76D5

Q37964490-47705EAE-9427-42CD-AA24-615E5004D9E7

Q37964490-73DBCA4C-F5EA-4701-A09D-11F0641A9A2D

Q37964490-784AE9D8-E0A0-443C-B5D0-6B24BDD1BC3B

Q37964490-8E9EAF00-CB79-4EC5-9631-876DE86497AD

Q37964490-9924E345-6A5C-4BA2-A7A2-E922382C8EF1

Q37964490-AE0CA599-D5B1-4104-9984-7190877D0984

Q37964490-AFB50973-1D79-4542-A293-8DE9498B7C4D

Q37964490-C740B85C-32C1-4659-885F-52D519B78BB9

Q37964490-CF6A99FB-E920-4B5E-9CD1-F161B213841A

P2860

Q37964490-0C56FAD2-AA31-4F9E-AEFB-871B7453556D

Q37964490-0C97D93D-82D5-442D-96B7-630B12B6B4BB

Q37964490-11640D50-BE88-4D63-BDFC-B1A2954040E6

Q37964490-136F6C7B-5DE9-40E2-AC09-C624183DCFD8

Q37964490-1578F222-11F0-4E43-BAA8-C8D048915310

Q37964490-19A818FC-7A4F-4ED9-91C8-2A4CC5C853B8

Q37964490-1A0356A7-3DA9-402A-A469-69786AA3154C

Q37964490-1DE4DFF1-24AC-44B3-8939-93F429FCB520

Q37964490-1E3752F0-D817-4E97-8D2F-FCDB766FF280

Q37964490-1F689D7A-8F92-4531-90CA-43BEB038E2F3

P2888

Q37964490-2D2322C9-1C25-4651-9C0B-BC10FDBA2CEC

P304

Q37964490-D407C5B9-3B01-4EE7-8D52-E784F0E55998

P31

Q37964490-D2B43353-3676-43ED-8ABB-773DD1FFC3A3

P356

Q37964490-AFC4D5A2-FBD2-44B5-8529-52971F97759B

P433

Q37964490-BD15E70A-6273-443A-A811-3FCC0C09787D

P478

Q37964490-ADB84B6B-2939-4CFE-8C30-28D160605DA0

P50

Q37964490-114005C2-4331-416A-BE7B-04114A8C41CB

Q37964490-3AEF39E0-6AD6-4070-85C2-C011255474DD

Q37964490-47B93754-AEF2-4A89-B56E-05C524A963AC

Q37964490-80A8C4E3-B1AE-4BDF-8F40-9D19C9EF2ADC

P577

Q37964490-5E59EA64-AF21-40B2-9DF6-BBD8A6EC2906

P5875

Q37964490-C6827F87-6C8F-4343-8059-FBCE1FC9D102

P698

Q37964490-75121DAB-EB0D-4296-BA0D-E1BFCA5F4631

P921

Q37964490-231ED56C-8FF2-4706-81CA-F63225BF3DC5

Q37964490-9226D791-3744-464C-9DDB-CD8C0BCBE788

P356

S00262-011-1162-8

P1433

Cancer Immunology, Immunotherapy

P1476

Recombinant IgE antibodies for ...... t towards clinical application

@en

P2093

Alexander Koers

http://www.w3.org/2001/XMLSchema#string

Amy E Gilbert

http://www.w3.org/2001/XMLSchema#string

Debra H Josephs

http://www.w3.org/2001/XMLSchema#string

Frank O Nestle

http://www.w3.org/2001/XMLSchema#string

James F Spicer

http://www.w3.org/2001/XMLSchema#string

Louise Saul

http://www.w3.org/2001/XMLSchema#string

Panagiotis Karagiannis

http://www.w3.org/2001/XMLSchema#string

Sarah M Rudman

http://www.w3.org/2001/XMLSchema#string

Sophia N Karagiannis

http://www.w3.org/2001/XMLSchema#string

Tihomir Dodev

http://www.w3.org/2001/XMLSchema#string

P2860

Total and functional parasite specific IgE responses in Plasmodium falciparum-infected patients exhibiting different clinical status

The killing of Leishmania major by human macrophages is mediated by nitric oxide induced after ligation of the Fc epsilon RII/CD23 surface antigen

Purified membrane and soluble folate binding proteins from cultured KB cells have similar amino acid compositions and molecular weights but differ in fatty acid acylation

Utility of serum HER2 extracellular domain assessment in clinical decision making: pooled analysis of four trials of trastuzumab in metastatic breast cancer

Therapeutic antibodies: current state and future trends--is a paradigm change coming soon?

Distinct role of macrophages in different tumor microenvironments

Recombinant human monoclonal igA antibody against CEA to recruit neutrophils to CEA-expressing cells.

The human immune response during cutaneous leishmaniasis: NO problem.

Monoclonal antibodies: versatile platforms for cancer immunotherapy.

The biology of IGE and the basis of allergic disease.

P2888

s00262-011-1162-8

P304

1547-1564

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S00262-011-1162-8

http://www.w3.org/2001/XMLSchema#string

P433

9

http://www.w3.org/2001/XMLSchema#string

P478

61

http://www.w3.org/2001/XMLSchema#string

P50

Andrew J. Beavil

Philip J Blower

P577

2011-12-03T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

51851298

http://www.w3.org/2001/XMLSchema#string

P698

22139135

http://www.w3.org/2001/XMLSchema#string

P921